Flumatinib, indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia, is a structural analog of imatinib and has shown higher potency than imatinib as a BCR-ABL inhibitor. In this paper, the metabolic profile of flumatinib was studied. It was found that CYP3A4 and CYP2C8 were the main cytochrome P450 enzyme substyles catalyzing the metabolism of flumatinib, and CYP3A4 has a stronger metabolic ability for flumatinib than CYP2C8. Erythromycin, cyclosporine, and voriconazole can inhibit the metabolism of flumatinib . Accordingly, co-administration of erythromycin and cyclosporine with flumatinib increased the plasma concentration and the systemic exposure of flumatinib in rats, which indicated that lower doses should be considered in clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1691/ph.2020.0068 | DOI Listing |
Pediatr Pulmonol
December 2024
Dr. von Haunersches Kinderspital, University of Munich, German Center for Lung Research (DZL), Munich, Germany.
Background: Biallelic ATP-binding cassette subfamily A member 3 (ABCA3) variants can cause interstitial lung disease in children and adults, for which no proven treatments exist. Recent in vitro evidence suggested that cyclosporine A (CsA) could correct some ABCA3 variants, however for other variants this is unknown and no data in patients exist.
Methods: We retrieved the clinical data of two children aged 2 and 4 years carrying homozygous ABCA3 variants (G210C and Q1045R, respectively) and empiric CsA treatment from the Kids Lung Register database.
J Pediatr Ophthalmol Strabismus
September 2024
Purpose: To evaluate the efficacy and safety of oral azithromycin treatment combined with topical antibiotic and anti-inflammatory agents in pediatric patients with chronic severe bilateral blepharokeratoconjunctivitis.
Methods: Patients younger than 14 years with chronic and severe bilateral blepharokeratoconjunctivitis were reviewed retrospectively. Consecutive patients receiving oral azithromycin treatment were included.
Cent Nerv Syst Agents Med Chem
April 2024
Nutrition and Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Seizures are a common presenting symptom of the central nervous system (CNS) and could occur from infections (such as toxins) or drugs.
Objective: The aim of this study was to present a systematic review of the association between infections, seizures, and drugs.
Methods: Through February 18, 2024, according to the PRISMA guidelines and based on the PICO standard format, relevant, in-depth consequent guide approach and evidence-based options were selected associated with a knowledgeable collection of current, high-quality manuscripts.
Heliyon
December 2023
Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Background: , known as Yarrow, is a medicinal plant in the family which is one of the oldest known botanicals used by humans and itis one of the most important medicinal plants in the pharmaceutical field. Purpose: This review discusses pharmacodynamics, pharmacokinetics, and mechanism of action of the most important component of . There are a variety of same species such as white, red and yellow yarrow and all of these species have been discussed in this manuscript.
View Article and Find Full Text PDFCureus
January 2023
Department of Rheumatology, The University of Toledo, Toledo, USA.
Linear immunoglobulin A (IgA) bullous dermatosis (LABD) is an autoimmune disease affecting children or adults that leads to subepithelial vesiculobullous lesions on the skin and/or mucosa. Due to the histologic and clinical appearance of the disease with tense and pruritic blisters, direct immunofluorescence is required for diagnosis, which features the characteristic linear deposition of IgA autoantibodies along the basement membrane zone. LABD can be idiopathic, drug-induced, or associated with a systemic disease such as inflammatory bowel disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!